Evidence map›Paper›PMID 42227265›Full record

ArticleBritish journal of haematology2026

Real-world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single-centre experience.

Taku Kikuchi, Ukyo Kondo, Shotaro Sugita, Miyu Watanabe, Chiaki Matsumoto, Moe Nomura-Yogo, Kodai Kunisada, Kota Sato, Tomomi Takei, Yu Abe and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Taku KikuchiDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.ORCID https://orcid.org/0000-0002-3210-7756
Ukyo KondoDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Shotaro SugitaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Miyu WatanabeDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Chiaki MatsumotoDepartment of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan.
Moe Nomura-YogoDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.ORCID https://orcid.org/0009-0005-1041-5036
Kodai KunisadaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Kota SatoDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Tomomi TakeiDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Yu AbeDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Osamu HosoyaDepartment of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan.
Tadao IshidaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Nobuhiro TsukadaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

idecabtagene vicleucelmultiple myelomareal‐world outcomes

Identifiers

PMID42227265
PMCPMC13462183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.